Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug
The Trump administration is set to launch two pilot programs aimed at implementing ‘most favored…
Newswire
Symbiosis Begins Commercial Manufacturing at New FDA-Inspected Facility
Symbiosis Pharmaceutical Services (Symbiosis) has successfully manufactured its first batch of 10,000 vials at its…
Medicus Pharma Partners with Reliant AI to Enhance Clinical Trial Analytics
Medicus Pharma Ltd. has announced a non-binding letter of intent (LOI) with Reliant AI Inc.…
Ipsen Secures Antibody-Drug Conjugate from Simcere Zaiming for $45 Million
Ipsen has announced a significant expansion of its portfolio by securing access to an antibody-drug…
Radiopharmaceutical Specialist Aktis Seeks an IPO
Aktis, a rising player in the radiopharmaceutical sector, has announced its intention to pursue an…
Boehringer Ingelheim Partners with Rectify to Develop Oral Medications for Chronic Kidney Disease
Boehringer Ingelheim has entered into a strategic partnership with Boston-based startup Rectify to develop oral…
AstraZeneca Invests $100 Million Upfront in Jacobio’s Pan-KRAS Inhibitor
AstraZeneca is committing $100 million upfront to acquire ex-China rights for Jacobio Pharma’s early-stage cancer…
CMMI Proposes New Models to Lower Drug Prices to International Rates for Medicare Parts B, D
The Centers for Medicare & Medicaid Services’ (CMS) Innovation Center has unveiled two new drug…
Trump Administration Secures Pricing Deals with Nine Additional Pharma Companies
The Trump administration has successfully negotiated pricing agreements with nine more pharmaceutical companies, leaving only…
Boehringer’s Jascayd Quickly Expands Lung Disease Reach with New FDA Nod
Boehringer Ingelheim’s Jascayd has received FDA approval to target progressive pulmonary fibrosis, marking a significant…